Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Ying, X.; Tina, S.; Yao, J. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342. [Google Scholar] [CrossRef] [PubMed]
- Chi, W.; Warner, R.R.P.; Chan, D.L.; Warner, R.; Chan, D.; Singh, S.; Segelov, E.; Strosberg, J.; Wisnivesky, J.; Kim, M. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas 2018, 47, 321–325. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; Jann, H.; Prasad, V.; Drozdov, I.; Modlin, I.M.; Kidd, M. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology 2017, 104, 170–182. [Google Scholar] [CrossRef] [PubMed]
- Cives, M.; Strosberg, J. Radionuclide Therapy for Neuroendocrine Tumors. Curr. Oncol. Rep. 2017, 19, 9. [Google Scholar] [CrossRef] [PubMed]
- Bar-Moshe, Y.; Mazeh, H.; Grozinsky-Glasberg, S. Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J. Gastrointest. Endosc. 2017, 9, 153–161. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Scott, A.T.; Breheny, P.J.; Keck, K.J.; Bellizzi, A.M.; Dillon, J.S.; O’Dorisio, T.M.; Howe, J. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery 2019, 165, 166–177. [Google Scholar] [CrossRef] [PubMed]
- Saxena, A.; Chua, T.C.; Perera, M.; Chu, F.; Morris, D.L. Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. Surg. Oncol. 2012, 21, e131–e141. [Google Scholar] [CrossRef] [PubMed]
- Reubi, J.C.; Maurer, R.; von Werder, K.; Torhorst, J.; Klijn, J.G.; Lamberts, S.W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987, 47, 551–558. [Google Scholar] [PubMed]
- Bushnell, D.L., Jr.; O’Dorisio, T.M.; O’Dorisio, M.S.; Menda, Y.; Hicks, R.J.; Van Cutsem, E.; Baulieu, J.L.; Borson-Chazot, F.; Anthony, L.; Benson, A.B.; et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 2010, 28, 1652–1659. [Google Scholar] [CrossRef] [PubMed]
- Chan, J.A.; Faris, J.E.; Murphy, J.E.; Blaszkowsky, L.S.; Kwak, E.L.; McCleary, N.J.; Fuchs, C.S.; Meyerhardt, J.A.; Ng, K.; Zhu, A.X.; et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J. Clin. Oncol. 2017, 35 (Suppl_4), 228. [Google Scholar] [CrossRef]
- Fine, R.L.; Gulati, A.P.; Krantz, B.A.; Moss, R.A.; Schreibman, S.; Tsushima, D.A.; Mowatt, K.B.; Dinnen, R.D.; Mao, Y.; Stevens, P.D.; et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother. Pharmacol. 2013, 71, 663–670. [Google Scholar] [CrossRef] [PubMed]
- Krenning, E.P.; Kooij, P.P.; Bakker, W.H.; Breeman, W.A.; Postema, P.T.; Kwekkeboom, D.J.; Oei, H.Y.; de Jong, M.; Visser, T.J.; Reijs, A.E.; et al. Radiotherapy with a radiolabeled so-matostatin analogue, [111ln-DTPA-D-Phe1]-octreotide. A case history. Ann. N. Y. Acad. Sci. 1994, 733, 496–506. [Google Scholar] [CrossRef] [PubMed]
- Harris, P.E.; Zhernosekov, K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front. Endocrinol. 2022, 13, 941832. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lutetium (177Lu) Oxodotreotide (Lutathera): CADTH Reimbursement Recommendation: Indication: For the Treatment of Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor (SSR)–Positive Pancreatic Neuroendocrine Tumours (pNETs) in Adults Whose Disease Has Progressed after Treatment with a Somatostatin Analogue (SSA), Unless There Is a Contraindication or Intolerance [Internet]; Canadian Agency for Drugs and Technologies in Health: Ottawa, ON, Canada, 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK602624/ (accessed on 1 September 2023).
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009, 42, 377–381. [Google Scholar] [CrossRef] [PubMed]
- Harris, P.A.; Taylor, R.; Minor, B.L.; Elliott, V.; Fernandez, M.; O’Neal, L.; McLeod, L.; Delacqua, G.; Delacqua, F.; Kirby, J.; et al. The REDCap consortium: Building an international community of software partners. J. Biomed. Inform. 2019, 95, 103208. [Google Scholar] [CrossRef] [PubMed]
- Sistani, G.; Sutherland, D.E.K.; Mujoomdar, A.; Wiseman, D.P.; Khatami, A.; Tsvetkova, E.; Reid, R.H.; Laidley, D.T. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr. Oncol. 2020, 28, 115–127. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- White, B.E.; Russell, B.; Remmers, S.; Rous, B.; Chandrakumaran, K.; Wong, K.F.; Van Hemelrijck, M.; Srirajaskanthan, R.; Ramage, J.K. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012–2018: A Retrospective, Population-Based Study. Cancers 2023, 15, 1863. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Hallet, J.; Law, C.H.; Karanicolas, P.J.; Saskin, R.; Liu, N.; Singh, S. Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases. Cancer 2015, 121, 2214–2221. [Google Scholar] [CrossRef] [PubMed]
- Hallet, J.; Law, C.H.; Cukier, M.; Saskin, R.; Liu, N.; Singh, S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015, 121, 589–597. [Google Scholar] [CrossRef] [PubMed]
Demographic Information | PRRT Centre | Non-PRRT Centre |
---|---|---|
Biological sex (%) | ||
Female | 39 | 43.5 |
Male | 61 | 56.5 |
Median age at diagnosis [IQR] | 61 [53, 66] | 61 [54, 67] |
Median height [Min, Max] (cm) | 173 [151, 193] | 168 [149, 188] |
Median weight [Min, Max] (kg) | 81 [45.0, 122] | 81.5 [46.0, 148] |
Living within a metropolitan area (%) | 61 | 47.4 |
Median days from referral to medical oncology consultation | 26 | 15 |
Median distance to PRRT centre (km) | 112 | 569 |
Clinical stage (%) | ||
Stage I | 13 | 20.9 |
Stage II | 14.3 | 25.2 |
Stage III | 10.4 | 7.8 |
Stage IV | 62.3 | 46.1 |
Median Ki67 value | 6 | 5 |
Tumor grade (%) | ||
Grade 1 | 27.9 | 27.2 |
Grade 2 | 44.1 | 30.4 |
Grade 3 | 5.9 | 9.8 |
Unknown | 22.1 | 10.9 |
Tumor Characteristic | Male (N = 112) | Female (N = 79) | p-Value |
---|---|---|---|
Differentiation | 0.8 | ||
Well | 66 (59%) | 49 (62%) | |
Moderate | 2 (1.8%) | 0 (0%) | |
Poor | 2 (1.8%) | 1 (1.3% | |
Unknown | 42 (38%) | 29 (37%) | |
Stage | 0.6 | ||
I | 17 (15%) | 17 (22%) | |
II | 23 (21%) | 16 (20%) | |
III | 9 (8.0%) | 8 (10%) | |
IV | 63 (56%) | 38 (48%) |
Treatment Modality | Patients Receiving Treatment (%) | Patient Characteristics |
---|---|---|
Surgery for Primary Tumor | 56 | 40% curative intent |
Octreotide | 34 | 66% had progressive disease 82% had metastases at start |
Lanreotide | 30 | 77% had progressive disease 75% had metastases at start |
Chemotherapy | 30 | 94% had progressive disease and 91% had metastases at start 45% of treatments ceased due to disease progression 18% of treatments were completed |
PRRT | 29 | Median number of cycles was 4 [1, 13] Of all treatment instances, 80% had progressive disease and 96% had metastases at treatment start 77% were completed |
Targeted Therapy | 22 | 85% had progressive disease 89% had metastases at treatment start |
Surgery for Metastases | 16 | 63% targeted the liver 31% had curative intent |
Locoregional Ablative Therapy | 16 | 99% of ablations targeted metastases |
Radiation Therapy | 15 | 93% of treatments were done with non-curative intent 100% had progressive disease 93% had metastases at treatment start |
Lanreotide | 30 | 77% had progressive disease 75% had metastases at start |
Chemotherapy | 30 | 94% had progressive disease and 91% had metastases at start 45% of treatments ceased due to disease progression 18% of treatments were completed |
PRRT Treatment Characteristics | PRRT Centre | Non-PRRT Centre |
---|---|---|
Total number of pNET patients | 77 | 112 |
Number of patients undergoing PRRT | 46 | 7 |
Median distance to PRRT centre (km) | 112 [IQR 34–193] | 569 [IQR 551–593] |
Median distance to PRRT centre if PRRT was used (km) | 158 [IQR 85–541] | 541 [IQR 155–576] |
Patients undergoing PRRT with well-differentiated pNET (%) | 80 | 43 |
Patients undergoing PRRT with stage IV pNET (%) | 76 | 71 |
Surgery for primary tumor | 74 | 54 |
Median number of cycles [Min, Max] | 4 [1–13] | 4 [1–5] |
pNET Patient Survival Status | PRRT | No PRRT |
---|---|---|
Alive (%) | 47.2 | 52.9 |
Median Age at Diagnosis | 58 | 62 |
Lost to Follow up (%) | 1.9 | 2.9 |
Deceased (%) | 50.9 | 44.2 |
Of Deceased NET-Related Death (%) | 33.3 | 65.0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nair, G.; Black, M.; Baer, K.; Welch, S.; Laidley, D.T.; Goodwin, R.; Leung, M.; Phillips, W.J.; Vickers, M.; Asmis, T.; et al. Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres. Curr. Oncol. 2025, 32, 86. https://doi.org/10.3390/curroncol32020086
Nair G, Black M, Baer K, Welch S, Laidley DT, Goodwin R, Leung M, Phillips WJ, Vickers M, Asmis T, et al. Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres. Current Oncology. 2025; 32(2):86. https://doi.org/10.3390/curroncol32020086
Chicago/Turabian StyleNair, Gautham, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, and et al. 2025. "Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres" Current Oncology 32, no. 2: 86. https://doi.org/10.3390/curroncol32020086
APA StyleNair, G., Black, M., Baer, K., Welch, S., Laidley, D. T., Goodwin, R., Leung, M., Phillips, W. J., Vickers, M., Asmis, T., Marginean, H., & Tsvetkova, E. (2025). Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres. Current Oncology, 32(2), 86. https://doi.org/10.3390/curroncol32020086